Latest Clinical trial Stories
Study of RNA interference drug presented at AACR Annual Meeting 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen). Early results from the phase I, first in-human study of an RNA interference (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10,...
MarketReportsOnline.com offers the latest guidebook for application of imported traditional Chinese medicine and natural medicine registration DALLAS, April 10, 2013 /PRNewswire-iReach/ -- China Pharmaceutical Guidebook Series (1) 2013 Edition Latest Chinese Regulations for Imported Drug Registration: A Comprehensive Guidebook for Foreign Pharmaceutical Companies By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) reported by the "2012:...
- FDA IDE approval supports expansion of SMART Clinical Trial to 20 Clinical Sites REDWOOD CITY, Calif., April 10, 2013 /PRNewswire/ -- Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has completed a pre-planned interim review of safety results of the company's SMART Clinical Trial evaluating its Intracept therapy for chronic...
All amounts are in US dollars QUÉBEC CITY, April 10, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. ("Ergomed") for AEZS-108 in endometrial cancer. Ergomed was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase 3 trial with AEZS-108 in endometrial cancer....
Inflamax Research Inc. today announced that it has been selected by Allergy Therapeutics (UK) Ltd. (ATL) (AGY:LSE), as the CRO to conduct ATL’s pivotal Phase III study for Grass MATAMPL product for US-FDA registration. Toronto, ON (PRWEB) April 09, 2013 The study will involve the location of mobile EEC at centers in three metropolitan areas in the US Midwest, US North East and in Canada, with several investigative sites at each node contributing subjects to the study. The screening and...
NORCROSS, Ga., April 9, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis. The Phase 1 Clinical Trial is entitled, "A Multi-Center, Partially Blinded, Maximum...
Research for diabetes is far more focused on drug therapies than preventive measures, and tends to exclude children and older people who have much to gain from better disease management, according to a Duke Medicine study. By analyzing nearly 2,500 diabetes-related trials registered in ClinicalTrials.gov from 2007-10, the authors provide a broad overview of the research landscape for diabetes. The effort is part of the Clinical Trials Transformation Initiative, a public-private partnership...
HOUSTON, April 5, 2013 /PRNewswire/ -- Novum Pharmaceutical Research Services, a leading contract research organization (CRO) serving the pharmaceutical industry in Phase I-Phase IV clinical trials and related services, announced today the opening of a new early-stage clinical facility in Houston, TX. The 55,000 square foot facility is scheduled to be operational in August, 2013. "This exciting new facility reflects Novum's continued growth and our deep commitment to our clients'...
SAN DIEGO, April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P(1)) receptor for the potential treatment of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64...
Now Enrolling Patients into Third Dosing Cohort SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The...
